ArticleTrials2025
Efficacy and safety of the COMBO endoscopy oropharyngeal airway in gastrointestinal endoscopy: a study protocol for a multicenter randomized controlled trial.
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06081647 (The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway Reduce the Incidence of Hypoxia in Patients Undergoing Gastrointestinal Endoscopy Sedated With Propofol.), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway Reduce the Incidence of Hypoxia in Patients Undergoing Gastrointestinal Endoscopy Sedated With Propofol.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHypoxia is one of the most common adverse events of sedated gastrointestinal (GI) endoscopy. It can cause coronary ischemia and permanent nervous system damage, potentially leading to death if not promptly addressed. This study aims to examine the efficacy and safety of the COMBO (capnography monitoring bite block oxygenation) endoscopy oropharyngeal airway in patients undergoing sedated GI endoscopy.
methodsA multicenter randomized, open-label, two-arm parallel-group superiority clinical trial with an active comparator will be conducted to evaluate the impact of the COMBO endoscopy oropharyngeal airway on the incidence of hypoxia. This study will include patients (n = 1200) undergoing GI endoscopy under propofol sedation. Written informed consent will be obtained from them. The participants (patients undergoing elective upper gastrointestinal endoscopic surgery, ≥ 18 years old and ≤ 60 years old, American Society of Anesthesiologists Grade I-II, expected inspection time ≤ 45 min) will be randomly assigned to a conventional nasal cannula (Arm 1)or the COMBO endoscopy oropharyngeal airway group (Arm 2). The intervention group will be administered the COMBO endoscopy oropharyngeal airway correspondingly. The primary objective is the incidence of hypoxia (75% ≤ SpO DISCUSSION: The COMBO endoscopy oropharyngeal airway is a novel method for oxygenation and airway management. This study is aimed at investigating whether the COMBO endoscopy oropharyngeal airway can reduce the incidence of hypoxia in patients during gastrointestinal endoscopy under sedation with propofol. If successful, our proposal could play a pivotal role that represents a significant advancement in airway management in preventing hypoxemia during GI endoscopy under propofol sedation.
trial registrationClinicalTrials.gov NCT06081647, registered on October 15, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.